Drug Search Results
More Filters [+]

Fingolimod

Alternative Names: fingolimod, gilenya, fty720, fingolimob, fty 720, tascenso odt
Latest Update: 2024-11-23
Latest Update Note: Clinical Trial Update

Product Description

Fingolimod (FTY720, Gilenya) was the first US Food and Drug Administration-approved oral therapy for relapsing forms of multiple sclerosis (MS).  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30625282/)

Mechanisms of Action: S1P1 Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: Multiple Sclerosis

Known Adverse Events: Abdominal Pain | Back Pain | Headache | Pain Unspecified | Sinusitis | Diarrhea | Influenza, Human

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fingolimod

Countries in Clinic: Australia, France, Germany, Romania, Slovakia, Spain

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Multiple Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CFTY720D2311

P3

Unknown Status

Multiple Sclerosis

2029-07-12

2018-001292-21

P3

Active, not recruiting

Multiple Sclerosis

2025-07-04

ACTRN12618002016213

P1

Not yet recruiting

Multiple Sclerosis

None

Recent News Events